Title : MDX-1097
Text : {{Orphan|date=June 2014}}

'''MDX-1097''' (also called '''IST-1097''' or '''KappaMab''') is a [[monoclonal antibody therapy]] being assessed in Phase IIb clinical trials as a treatment for [[multiple myeloma]], a type of white blood cell cancer.<ref>{{cite web|url=https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=371289 | title = Australian New Zealand Clinical Trials Registry Number12616001164482}}</ref> It is a [[chimeric antibody|chimeric]] version of the mouse [[monoclonal antibody]] K-1-21.<ref name="pmid21466897">{{cite journal |vauthors=Hutchinson AT, Alexova R, Bockhorni V, Ramsland PA, Jones DR, Jennings CV, Broady K, Edmundson AB, Raison RL | title = Characterization of a unique conformational epitope on free immunoglobulin kappa light chains that is recognized by an antibody with therapeutic potential | journal = Molecular Immunology | volume = 48 | issue = 9–10 | pages = 1245–52 |date=May 2011 | pmid = 21466897 | doi = 10.1016/j.molimm.2011.03.003 }}</ref> MDX-1097 targets kappa free [[immunoglobulin light chain]]s which are found on the surface of some kappa light chain-restricted myeloma cells.<ref name="pmid20817866">{{cite journal |vauthors=Hutchinson AT, Ramsland PA, Jones DR, Agostino M, Lund ME, Jennings CV, Bockhorni V, Yuriev E, Edmundson AB, Raison RL | title = Free Ig light chains interact with sphingomyelin and are found on the surface of myeloma plasma cells in an aggregated form | journal = Journal of Immunology | volume = 185 | issue = 7 | pages = 4179–88 |date=Oct 2010 | pmid = 20817866 | doi = 10.4049/jimmunol.1001956 }}</ref><ref name=":0">{{cite journal|title=Preclinical and clinical development of an anti-kappa free light chain mAb for multiple myeloma|journal=Molecular Immunology|volume=67|issue=2 Pt A|pages=89–94|pmid=25964097|doi=10.1016/j.molimm.2015.04.013|year=2015|author1=Hutchinson|first1=A. T.|last2=Jones|first2=D. R.|last3=Raison|first3=R. L.}}</ref>

MDX-1097 was originally developed by scientists at Immune System Therapeutics Ltd.<ref name=":0" /> In 2015, Haemalogix Pty Ltd acquired the rights to MDX-1097 and are now taking it through late stage clinical testing.<ref>{{Cite web|url=https://www.mcgrathnicol.com/app/uploads/Circular-to-creditors-25-May-20151.pdf|title=Immune System Therapeutics Circular to Creditors 25 May 2015|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref><ref>{{Cite web|url=http://www.haemalogix.com/science/clinical-trials/5|title=Haemalogix Website - MDX-1097 Clinical Trials|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref>

== References ==
{{reflist|35em}}

[[Category:Medical procedures]]


{{antineoplastic-drug-stub}}
{{monoclonal-antibody-stub}}
